Project Grant R01NS136297

Award Date 12/1/24
Completion Date 11/30/29
Dollars Obligated $691K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $657,958 to Boston University to conduct research on the cellular and network mechanisms underlying epilepsy and neuromodulation. The research aims to elucidate the neuronal mechanisms of epileptic activity, the relationship between spike ripples and seizures, and the...
This $256,500 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to develop a highly personalized approach to thalamic neuromodulation for the treatment of drug-resistant epilepsy. The key products and services to be delivered include: Mapping thalamocortical effective connectivity using single pulse electrical stimulation during...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $408,400 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and evaluate a novel wearable magnetoencephalography (MEG) system for use in children with epilepsy. The funding will support Aim 1, the development of an age-appropriate, movement-resistant OPM-MEG...
This $580,070 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports a 5-year research project at Stanford University. The research aims to map the connectivity of key thalamic subregions in the human brain, examine their roles in seizure propagation and memory formation, and evaluate the causal relevance of the anterior nucleus of...
This $638,718 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop and validate innovative techniques for selective, targeted neurostimulation of peripheral nerves. The key products and services to be delivered include: Testing the hypothesis that interferential current stimulation (I2CS) can selectively activate specific nerve...
The federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is providing $1,602,423.00 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for the development and evaluation of an improved functional magnetic resonance imaging (fMRI) acquisition strategy. The project aims to enhance the quality of fMRI for...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $2,359,174 Project Grant under the 21st Century Cures Act - Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the biophysical mechanisms of cortical microstimulation. The project aims to develop a more mechanistic understanding of how direct local electrical stimulation...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $426,250 Project Grant under CFDA 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders, to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. This 2-year grant will fund research using cutting-edge voltage imaging to examine how interactions between specific neuronal circuit elements in the hippocampus relate to the development of temporal lobe...
This Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of scalable, quantitative methods to map epileptic networks and guide surgical treatment for epilepsy patients. The $148,956 award to The Trustees of the University of Pennsylvania will fund the creation of standardized analytical tools to...
The federal Project Grant award R21NS135482 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $438,836 award, with a period of performance from August 15, 2024 to July 31, 2026, aims to develop a unified paradigm using simultaneous multimodal measurement of scalp EEG and intracranial EEG (iEEG) signals to estimate whole-brain electrophysiological...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is providing $690,763 to Brigham & Women's Hospital Inc. to optimize neuromodulation therapies for epilepsy. The key objectives are to: 1) identify patient-specific brain connectivity networks and stimulation fields crucial for positive outcomes with responsive neurostimulation (RNS) treatment; 2) investigate whether stimulating during low-risk seizure states enhances RNS effectiveness; and 3) explore circadian fluctuations in neural activity as a predictor of patient response. The award will fund research activities at Brigham & Women's Hospital and includes a sub-award to Massachusetts General Hospital to provide RNS system data, clinical information, and analysis support. Successful completion of these aims could lead to improved targeting of neuromodulation therapies, accelerated patient benefits, and reduced unnecessary surgical procedures.

Generated 6/10/25, 2:42 AM